Literature DB >> 26728470

5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.

Ana O Hoff1, Alfredo Berruti2.   

Abstract

Adrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a significant effort has been made to develop multinational, collaborative studies to better understand the pathogenesis and clinical features of this rare disease in attempt to improve the therapeutic strategies and patient outcome. The results of both standard and newer treatments are discussed in this review as well as the recent discovery of pathways involved in ACC pathogenesis that provide the rationale to introduce new molecular target therapies. Finally, remaining issues regarding how to improve available therapies in adjuvant setting are raised and addressed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26728470     DOI: 10.1007/s12672-015-0241-2

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  39 in total

1.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

2.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy.

Authors:  Florence de Fraipont; Michelle El Atifi; Nadia Cherradi; Gwennaelle Le Moigne; Geneviève Defaye; Rémi Houlgatte; Jérôme Bertherat; Xavier Bertagna; Pierre-François Plouin; Eric Baudin; François Berger; Christine Gicquel; Olivier Chabre; Jean-Jacques Feige
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Adjuvant and definitive radiotherapy for adrenocortical carcinoma.

Authors:  Aaron Sabolch; Mary Feng; Kent Griffith; Gary Hammer; Gerard Doherty; Edgar Ben-Josef
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-01       Impact factor: 7.038

4.  Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Berruti; E Baudin; H Gelderblom; H R Haak; F Porpiglia; M Fassnacht; G Pentheroudakis
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

5.  Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.

Authors:  Martin Fassnacht; Stefanie Hahner; Buelent Polat; Ann-Cathrin Koschker; Werner Kenn; Michael Flentje; Bruno Allolio
Journal:  J Clin Endocrinol Metab       Date:  2006-08-08       Impact factor: 5.958

6.  Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.

Authors:  Aaron Sabolch; Tobias Else; Kent A Griffith; Edgar Ben-Josef; Andrew Williams; Barbra S Miller; Francis Worden; Gary D Hammer; Shruti Jolly
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-05       Impact factor: 7.038

7.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

8.  The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

Authors:  Ciara O'Sullivan; Maureen Edgerly; Margarita Velarde; Julia Wilkerson; Aradhana M Venkatesan; Stefania Pittaluga; Sherry X Yang; Dat Nguyen; Sanjeeve Balasubramaniam; Tito Fojo
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

9.  Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.

Authors:  Maria Cristina De Martino; Abir Al Ghuzlan; Sebastien Aubert; Guillaume Assié; Jean-Yves Scoazec; Sophie Leboulleux; Christine Do Cao; Rossella Libè; Cécile Nozières; Marc Lombès; François Pattou; Francoise Borson-Chazot; Ségolène Hescot; Clement Mazoyer; Jacques Young; Isabelle Borget; Annamaria Colao; Rosario Pivonello; Jean-Charles Soria; Jerome Bertherat; Martin Schlumberger; Ludovic Lacroix; Eric Baudin
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

10.  Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.

Authors:  André P Fay; Sabina Signoretti; Marcella Callea; Gabriela H Telό; Rana R McKay; Jiaxi Song; Ingrid Carvo; Megan E Lampron; Marina D Kaymakcalan; Carlos E Poli-de-Figueiredo; Joaquim Bellmunt; F Stephen Hodi; Gordon J Freeman; Aymen Elfiky; Toni K Choueiri
Journal:  J Immunother Cancer       Date:  2015-02-17       Impact factor: 13.751

View more
  3 in total

1.  Palbociclib inhibits proliferation of human adrenocortical tumor cells.

Authors:  Chiara Fiorentini; Martina Fragni; Guido A M Tiberio; Diego Galli; Elisa Roca; Valentina Salvi; Daniela Bosisio; Cristina Missale; Massimo Terzolo; Maurizio Memo; Alfredo Berruti; Sandra Sigala
Journal:  Endocrine       Date:  2017-03-06       Impact factor: 3.633

2.  High TNFSF13B expression as a predictor of poor prognosis in adrenocortical carcinoma.

Authors:  Yongxin Mao; Parehe Alimu; Chenghe Wang; Wenming Ma; Ran Zhuo; Fukang Sun
Journal:  Transl Androl Urol       Date:  2021-08

Review 3.  Primary malignant tumors of the adrenal glands.

Authors:  Madson Q Almeida; Joao Evangelista Bezerra-Neto; Berenice B Mendonça; Ana Claudia Latronico; Maria Candida B V Fragoso
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.